G12C
· 4 retained evidence mentions
Source-grounded findings
Supporting evidence
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| variant | G12C | “In lung cancer, KRAS mutations, especially the G12C, favor aggressive tumor growth and resistance to standard therapies.” | 0.82 | literature_variant_regex_v2 |
| variant | G12C | “A novel avenue for the control of KRAS G12C and G12D mutations is made possible by flavonoids.” | 0.82 | literature_variant_regex_v2 |
| variant | G12C | “In KRAS, mutations of G12D and G12C are common.” | 0.82 | literature_variant_regex_v2 |
| variant | G12C | “We report the first documented case series of two lung adenocarcinoma patients demonstrating Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutations by reverse transcription-polymerase chain reaction techniques from Saudi Arabia.” | 0.82 | literature_variant_regex_v2 |